SynBioBeta Speaker
Jason Ryder
Oobli
Founder & CTO
Jason Ryder is the Founder and Chief Technology Officer of Oobli, a commercial-stage biotechnology company creating a new category of sweet protein ingredients and products for the food and beverage industry. Jason leads strategy for Oobli's technology, manufacturing platform, and portfolio of sweet protein products.
An expert in precision fermentation, Jason brings more than 20 years of experience in the engineering, scale-up, and commercialization of bio-based processes and products in the industrial biotech and food tech sectors. His professional work has ranged from small molecules to proteins with applications spanning sustainable chemicals, fuels, materials, foods, and food ingredients.
Jason earned a B.S. in Chemical Engineering from the University of Alabama and a Ph.D. in Chemical Engineering from the University of California, Berkeley. In 2018 he joined the UC Berkeley faculty in the Department of Chemical and Biomolecular Engineering, where he currently serves as Adjunct Professor and Executive Director of the Master of Bioprocess Engineering (MBPE) program.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Jason
This Year
•
-
Planetary Health
The New Main Course: Cultured Meat + Precision Fermentation
Plant-based food sales may be slowing, but that doesn’t mean innovation on the plate is stalling. Instead, momentum is shifting toward breakthrough technologies and smarter ingredient combinations. Cultured meat and precision fermentation are driving the next wave of sustainable ingredients, from proteins to cultured fats that bring authentic flavor and texture. This session highlights advances in cell culture, fermentation platforms, and scale-up strategies, along with the partnerships moving products from R&D to dining tables. Hear how food innovators are combining biology and culinary creativity to build a resilient, delicious, and sustainable future for global diets.
Get a Ticket
Featuring
Megan Thomas
Ladder 17
Founder & CEO
Launched the first CRISPR food in the US, award-winning storytelling podcast host.
Max Jamilly
Hoxton Farms
CEO & Co-founder
Cultivated-fat pioneer making alt-meat taste real.
Laura Kliman
Impossible Foods
Senior R&D Director
Making plant-based meat possible
Isabelle Decitre
ID Capital
Founder
Future Food Asia founder. Synbio food-systems investor.
Jason Ryder
Oobli
Founder & CTO
Turns exotic sweet proteins into craveable sweetness without sugar.
•
-
Planetary Health
The New Main Course: Cultured Meat + Precision Fermentation
Plant-based food sales may be slowing, but that doesn’t mean innovation on the plate is stalling. Instead, momentum is shifting toward breakthrough technologies and smarter ingredient combinations. Cultured meat and precision fermentation are driving the next wave of sustainable ingredients, from proteins to cultured fats that bring authentic flavor and texture. This session highlights advances in cell culture, fermentation platforms, and scale-up strategies, along with the partnerships moving products from R&D to dining tables. Hear how food innovators are combining biology and culinary creativity to build a resilient, delicious, and sustainable future for global diets.
Get a Ticket
Featuring
Megan Thomas
Ladder 17
Founder & CEO
Launched the first CRISPR food in the US, award-winning storytelling podcast host.
Max Jamilly
Hoxton Farms
CEO & Co-founder
Cultivated-fat pioneer making alt-meat taste real.
Laura Kliman
Impossible Foods
Senior R&D Director
Making plant-based meat possible
Isabelle Decitre
ID Capital
Founder
Future Food Asia founder. Synbio food-systems investor.
Jason Ryder
Oobli
Founder & CTO
Turns exotic sweet proteins into craveable sweetness without sugar.
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
